- Home
- DOUG vs CRDF Comparison
DOUG vs CRDF Comparison
Compare DOUG & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOUG
- CRDF
- Stock Information
- Founded
- DOUG 1911
- CRDF 1999
- Country
- DOUG United States
- CRDF United States
- Employees
- DOUG N/A
- CRDF N/A
- Industry
- DOUG Building operators
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DOUG Real Estate
- CRDF Health Care
- Exchange
- DOUG Nasdaq
- CRDF Nasdaq
- Market Cap
- DOUG 146.0M
- CRDF 133.5M
- IPO Year
- DOUG N/A
- CRDF N/A
- Fundamental
- Price
- DOUG $1.88
- CRDF $5.35
- Analyst Decision
- DOUG
- CRDF Strong Buy
- Analyst Count
- DOUG 0
- CRDF 3
- Target Price
- DOUG N/A
- CRDF $10.33
- AVG Volume (30 Days)
- DOUG 1.1M
- CRDF 3.9M
- Earning Date
- DOUG 11-07-2024
- CRDF 11-07-2024
- Dividend Yield
- DOUG N/A
- CRDF N/A
- EPS Growth
- DOUG N/A
- CRDF N/A
- EPS
- DOUG N/A
- CRDF N/A
- Revenue
- DOUG $966,442,000.00
- CRDF $688,000.00
- Revenue This Year
- DOUG $5.28
- CRDF $23.78
- Revenue Next Year
- DOUG $16.40
- CRDF N/A
- P/E Ratio
- DOUG N/A
- CRDF N/A
- Revenue Growth
- DOUG 1.86
- CRDF 49.57
- 52 Week Low
- DOUG $1.00
- CRDF $1.30
- 52 Week High
- DOUG $3.16
- CRDF $6.42
- Technical
- Relative Strength Index (RSI)
- DOUG 39.80
- CRDF 77.18
- Support Level
- DOUG $2.23
- CRDF $3.06
- Resistance Level
- DOUG $2.47
- CRDF $4.20
- Average True Range (ATR)
- DOUG 0.20
- CRDF 0.42
- MACD
- DOUG -0.08
- CRDF 0.26
- Stochastic Oscillator
- DOUG 7.34
- CRDF 91.43
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").